FDA Approves First New Advanced Head and Neck Cancer Treatment in a Decade
The U.S. Food and Drug Administration has granted accelerated approval to Rybrevant Faspro for adults with advanced head and neck squamous cell carcinoma.
🧠AI AnalysisPhoto: Medical Xpress
Key points
- FDA grants accelerated approval to Rybrevant Faspro for advanced HNSCC.
- First new drug approval for this patient group in a decade.
- Clinical trial showed a 42% overall response rate among 102 patients.
The U.S. Food and Drug Administration has cleared Janssen Biotech's Rybrevant Faspro, combining amivantamab and hyaluronidase-lpuj, to treat adults diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This authorization applies specifically to individuals whose condition has advanced despite previous treatments involving platinum-based chemotherapy and immunotherapy. Notably, this decision marks the first new drug approval for this patient group in ten years, though the treatment is not intended for human papillomavirus-associated oropharyngeal squamous cell carcinoma.
This regulatory decision is based on clinical data from a trial involving 102 patients with recurrent or metastatic HNSCC. The findings indicate that Rybrevant Faspro achieved an overall response rate of 42%, contrasted with a 20% rate seen with standard therapies. Furthermore, among the participants who responded to the medication, 56% maintained that response for a duration of six months or longer. Angelo De Claro, M.D., director of the FDA Oncology Center of Excellence, noted that the authorization offers a significant development for an illness where therapeutic choices have traditionally been restricted.
Because the authorization relies on an early-stage trial of 102 patients and was granted via the accelerated pathway, further clinical verification may be required to confirm long-term clinical benefits. Readers should consult qualified healthcare professionals regarding personal medical choices and treatment plans.
What to know
- Drug Name: Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
- Indication: Recurrent or metastatic HNSCC progressing after chemotherapy and immunotherapy
- Clinical Results: 42% overall response rate compared to 20% for current standard therapies
Source Medical Xpress — medicalxpress.com/news/2026-11-fda-drug-advanced-neck-squamous.html ↗
Read next
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …